Clinical Data Integration for Drug Safety End-to-end drug safety review pipeline that integrates FDA label information, FAERS spontaneous reports, disproportionality signal detection, pharmacogenomic biomarkers, clinical trial data, and published literature. Designed for regulatory assessments, pharmacovigilance, and clinical decision support. Guiding principles : 1. Label is ground truth -- FDA-approved labeling is the authoritative starting point for known safety information 2. Signals need context -- a FAERS signal without label or literature corroboration is hypothesis-generating, not con…